Table 1 Baseline characteristics of enrolled patients (FAS).

From: Anlotinib plus camrelizumab and chemotherapy as first-line treatment in patients with advanced esophageal squamous cell carcinoma

Characteristic

TCAC (n = 30)

TCC (n = 30)

P

Median age (IQR) — year

66 (59–70)

64(56–70)

0.535

Weight loss%,Mean ± SD

7.9 ± 1.9

7.2 ± 1.8

0.172

Age group, n (%)

> 65

16 (53.3)

14 (46.7)

0.606

≤ 65

14 (46.7

16 (53.3)

Sex, n (%)

Male

24 (80.0)

24 (80.0)

1

Female

6 (20.0)

6 (20.0)

Clinical stages*, n (%)

III

9 (30.0)

9 (30.0)

0.651

IVA

10 (33.3)

13 (43.3)

IVB

11 (36.7)

8 (26.7)

T-category*

T2

1 (3.3)

2 (6.7)

0.556

T3

20 (66.7)

16 (53.3)

T4

9 (30.0)

12 (40.0)

N-category*

N0-1

3 (10.0)

14 (46.7)

0.007

N2

17 (56.7)

11 (36.7)

N3

10 (33.3)

5 (16.7)

M-category*

M0

17 (56.7)

21 (70.0)

0.422

M1

13 (43.3)

9 (30.0)

Total diameter of target lesions (Mean ± SD—mm)

27.86 ± 12.29

28.78 ± 14.34

0.789

ECOG PS, n (%)

1

30 (100.0)

29 (96.7)

/

0

0 (0.0)

1 (3.3)

Localization*, n (%)

Cervical or UT

4 (13.3)

9 (30.0)

0.184

MT

21 (70.0)

14 (46.7)

LT

5 (16.7)

7 (23.3)

No. of organs with metastases

1

24 (80.0)

23(76.7)

1.000

≥ 2

6 (20.0)

7(23.3)

Sites of metastases

Lymph node

29 (96.7)

28 (93.3)

1.000

Lung

2 (6.7)

6 (20.0)

0.254

Liver

4 (13.3)

2 (6.7)

0.671

Bone

1 (3.3)

1 (3.3)

1.000

PD-L1 expression

≥ 10

23 (85.2)

22(81.5)

1.000

< 10

4 (14.8)

5(18.5)

Paclitaxel type, n (%)

Solvent-based

9 (30.0)

15(50.0)

0.114

Albumin bound

21 (70.0)

15(50.0)

Smoking, n (%)

Yes

18 (60.0)

19 (63.3)

0.791

No

12 (40.0)

11 (36.7)

Median smoking, (IQR)—pack-years

25 (0-43.9)

34(0-52.9)

0.280

Drinking, n (%)

Yes

15 (50.0)

16 (53.3)

0.796

No

15 (50.0)

14(46.7)

Dysphagia level#, n (%)

0–1

9 (30.0)

8 (26.7)

0.774

2–4

21 (70.0)

22 (73.3)

SCC, n (%)

Unknown

5 (16.7)

10 (33.3)

0.322

< 2.7ng/ml

17 (56.7)

13(43.3)

≥ 2.7ng/ml

8 (26.7)

7(23.3)

ALB, n (%)

Unknown

1(3.3)

0

0.453

< 40 g/L

11 (36.7)

13(43.3)

≥ 40 g/L

18 (60.0)

17(56.7)

ALB, Mean ± SD—g/L

40.7 ± 3.4

40.8 ± 3.7

0.931

LDH, n (%)

Unknown

1 (3.3)

0

0.418

≤ULN

24 (80.0)

23(76.7)

> ULN

5 (16.7)

7(23.3)

First dose reduction of paclitaxel, n (%)

Yes

21 (70.0)

19(63.3)

0.584

No

9 (30.0)

11 (36.7)

  1. The date of data cutoff was April 12, 2025. *, according to the 8th edition of the UICC/AJCC staging system.#, dysphagia scoring criteria can be found in eTable2. For continuous variables, use the t-test; for categorical variables, use Fisher’s exact test.
  2. IQR Interquartile Range, UT Upper thoracic, MT Middle thoracic, LT Lowerthoracic, SCC Squamous Cell Carcinoma Antigen, ALB Albumin, LDH Lactate Dehydrogenase, ULN Upper Limit of Normal.
Back to article page